Ascendiant Capital Maintains Buy on PAVmed, Lowers Price Target to $56

Benzinga Newsdesk www.benzinga.com Negative 57.0%

Neg 57% Neu 0% Pos 0%

Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:PAVM) with a Buy and lowers the price target from $65 to $56.